We held a webinar on Tuesday that allowed us to introduce our Biomarker Intelligence Maturity Model and to announce our new partnership with AdisInsight, a member of the Springer Nature family. We can assure you that the two are related. To see for yourself check out the webinar recording.
This week’s Chart of the Week attempts to communicate recent research on pure manual review of literature versus a combination of human and machine curation.
This week we took a look at FDA-cleared and approved IVDs for oncology, and grouped them based on whether they measure proteins or nucleic acids. Protein-based tests have historically been the dominant type used in the clinic, but this is changing rapidly. Based on our just-completed forecast, ...
This week's chart is an analysis of the number of clinical trials started each year in which biomarkers are being measured. The growth rate surprised even us, and we are projecting that five years from now, almost 2,500 clinical trials involving biomarkers will be started annually.
These are the drug developers using the largest number of unique biomarkers in their clinical trials, unique biomarkers being defined as those biomarkers that aren't being used by any other drug developers.